Quick answers
- What is Brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide used for?
- The FDA-approved label (Brompheniramine Maleate, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide, Sportpharm LLC, July 23, 2026) says: “Brompheniramine Maleate, Pseudoephedrine Hydrochloride, and Dextromethorphan Hydrobromide Syrup is indicated for relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the side effects of Brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide?
- The “Adverse Reactions” section of the FDA label (Brompheniramine Maleate, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide, Sportpharm LLC, July 23, 2026) begins: “The most frequent adverse reactions to Brompheniramine Maleate, Pseudoephedrine Hydrochloride, and Dextromethorphan Hydrobromide Syrup are: sedation; dryness of mouth, nose and throat; thickening of bronchial secretions; dizziness. Other adverse reactions may include: Dermatologic: Urticaria, drug rash, photosensitivity, pruritus. Cardiovascular System: Hypotension, hypertension, cardiac arrhythmias, palpitation.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the drug interactions of Brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide?
- The “Drug Interactions” section of the FDA label (Brompheniramine Maleate, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide, Sportpharm LLC, July 23, 2026) begins: “Monoamine oxidase inhibitors (MAOIs) Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAOIs and products containing dextromethorphan. In addition, MAOIs prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide have a boxed warning?
- No. None of the 18 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
- Has Brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide been recalled?
- FDA enforcement reports list 1 recall of products of this medicine; the newest started March 15, 2021 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide?
- 14 companies list prescription products of Brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide in the FDA NDC Directory, including Bryant Ranch Prepack, Acella Pharmaceuticals, LLC and Proficient Rx LP.
What Brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Brompheniramine Maleate, Pseudoephedrine Hydrochloride, and Dextromethorphan Hydrobromide Syrup is indicated for relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold.
— FDA label: Brompheniramine Maleate, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide, Sportpharm LLC, effective July 23, 2026. Read the full label on DailyMed →
Label quoted: the one for the most common form (syrup, oral), Brompheniramine Maleate, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide, Sportpharm LLC; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.
The FDA has 18 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 18 FDA labels for this medicine have a boxed warning.
Brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide side effects
Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.
The most frequent adverse reactions to Brompheniramine Maleate, Pseudoephedrine Hydrochloride, and Dextromethorphan Hydrobromide Syrup are: sedation; dryness of mouth, nose and throat; thickening of bronchial secretions; dizziness. Other adverse reactions may include: Dermatologic: Urticaria, drug rash, photosensitivity, pruritus. Cardiovascular System: Hypotension, hypertension, cardiac arrhythmias, palpitation.
Read more of this section
CNS: Disturbed coordination, tremor, irritability, insomnia, visual disturbances, weakness, nervousness, convulsions, headache, euphoria, and dysphoria. G.U. System: Urinary frequency, difficult urination. G.I. System: Epigastric discomfort, anorexia, nausea, vomiting, diarrhea, constipation. Respiratory System: Tightness of chest and wheezing, shortness of breath. Hematologic System: Hemolytic anemia, thrombocytopenia, agranulocytosis.
— FDA label: Brompheniramine Maleate, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide, Sportpharm LLC, effective July 23, 2026. Read the full label on DailyMed →
Brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide drug interactions
Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.
Monoamine oxidase inhibitors (MAOIs) Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAOIs and products containing dextromethorphan. In addition, MAOIs prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine.
Read more of this section
Concomitant administration of Brompheniramine Maleate, Pseudoephedrine Hydrochloride, and Dextromethorphan Hydrobromide Syrup and MAOIs should be avoided (see CONTRAINDICATIONS). Central nervous system (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs.
— FDA label: Brompheniramine Maleate, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide, Sportpharm LLC, effective July 23, 2026. Read the full label on DailyMed →
Brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide dosage
Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.
Adults and pediatric patients 12 years of age and over: 10 mL (2 teaspoonfuls) every 4 hours. Children 6 to under 12 years of age: 5 mL (1 teaspoonful) every 4 hours. Children 2 to under 6 years of age: 2.5 mL (½ teaspoonful) every 4 hours. Infants 6 months to under 2 years of age: Dosage to be established by a physician. Do not exceed 6 doses during a 24-hour period.
— FDA label: Brompheniramine Maleate, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide, Sportpharm LLC, effective July 23, 2026. Read the full label on DailyMed →
Brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide in pregnancy
Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.
Teratogenic Effects- Pregnancy Category C: Animal reproduction studies have not been conducted with Brompheniramine Maleate, Pseudoephedrine Hydrochloride, and Dextromethorphan Hydrobromide Syrup. It is also not known whether Brompheniramine Maleate, Pseudoephedrine Hydrochloride, and Dextromethorphan Hydrobromide Syrup can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. It should be given to a pregnant woman only if clearly needed.
Read more of this section
Reproduction studies of brompheniramine maleate (a component of Brompheniramine Maleate, Pseudoephedrine Hydrochloride, and Dextromethorphan Hydrobromide Syrup) in rats and mice at doses up to 16 times the maximum human doses have revealed no evidence of impaired fertility or harm to the fetus.
— FDA label: Brompheniramine Maleate, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide, Sportpharm LLC, effective July 23, 2026. Read the full label on DailyMed →
Brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide and breastfeeding
Quoted from the nursing mothers / lactation part of the FDA-approved label.
Because of the higher risk of intolerance of antihistamines in small infants generally, and in newborns and prematures in particular, Brompheniramine Maleate, Pseudoephedrine Hydrochloride, and Dextromethorphan Hydrobromide Syrup is contraindicated in nursing mothers.
— FDA label: Brompheniramine Maleate, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide, Sportpharm LLC, effective July 23, 2026. Read the full label on DailyMed →
When Brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide should not be used
Quoted from the “Contraindications” section of the FDA-approved label.
Hypersensitivity to any of the ingredients. Do not use in the newborn, in premature infants, in nursing mothers, or in patients with severe hypertension or severe coronary artery disease. Do not use dextromethorphan in patients receiving monoamine oxidase inhibitors (MAOIs) (see Drug Interactions). Antihistamines should not be used to treat lower respiratory tract conditions including asthma.
— FDA label: Brompheniramine Maleate, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide, Sportpharm LLC, effective July 23, 2026. Read the full label on DailyMed →
Brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide overdose
Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).
Signs and Symptoms: Central nervous system effects from overdosage of brompheniramine may vary from depression to stimulation, especially in children. Anticholinergic effects may be noted. Toxic doses of pseudoephedrine may result in CNS stimulation, tachycardia, hypertension, and cardiac arrhythmias; signs of CNS depression may occasionally be seen. Dextromethorphan in toxic doses will cause drowsiness, ataxia, nystagmus, opisthotonos, and convulsive seizures.
Read more of this section
Toxic Doses: Data suggest that individuals may respond in an unexpected manner to apparently small amounts of a particular drug. A 2½-year-old child survived the ingestion of 21 mg/kg of dextromethorphan exhibiting only ataxia, drowsiness, and fever, but seizures have been reported in 2 children following the ingestion of 13–17 mg/kg. Another 2½-year-old child survived a dose of 300–900 mg of brompheniramine. The toxic dose of pseudoephedrine should be less than that of ephedrine, which is estimated to be 50 mg/kg. Treatment: Induce emesis if patient is alert and is seen prior to 6 hours following ingestion. Precautions against aspiration must be taken, especially in infants and small children. Gastric lavage may be carried out, although in some instances tracheostomy may be necessary prior to lavage. Naloxone hydrochloride 0.005 mg/kg intravenously may be of value in reversing the CNS depression that may occur from an overdose of dextromethorphan. CNS stimulants may counter CNS depression. Should CNS hyperactivity or convulsive seizures occur, intravenous short-acting barbiturates may be indicated. Hypertensive responses and/or tachycardia should be treated appropriately. Oxygen, intravenous fluids, and other supportive measures should be employed as indicated.
— FDA label: Brompheniramine Maleate, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide, Sportpharm LLC, effective July 23, 2026. Read the full label on DailyMed →
Forms and how it is given
| Dosage forms | Syrup · Solution |
|---|---|
| Route | Oral |
| Prescription products | 18 in the FDA NDC Directory |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| brompheniramine maleate 2 mg/5 mL · dextromethorphan hydrobromide 10 mg/5 mL · pseudoephedrine hydrochloride 30 mg/5 mL solution | Generic | $0.0685–$0.0860 per mL 2 packages, lowest to highest |
| brompheniramine maleate 2 mg/5 mL · dextromethorphan hydrobromide 10 mg/5 mL · pseudoephedrine hydrochloride 30 mg/5 mL syrup | Generic | $0.0685–$0.0860 per mL 14 packages, lowest to highest |
NADAC list of November 11, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Bryant Ranch Prepack3 products
- Acella Pharmaceuticals, LLC2 products
- Proficient Rx LP2 products
- Eywa Pharma Inc1 product
- Ascend Laboratories, LLC1 product
- Padagis US LLC1 product
- PAI Holdings, LLC dba PAI Pharma1 product
- A-S Medication Solutions1 product
- Sportpharm LLC1 product
- Chartwell RX, LLC1 product
- Chartwell Governmental & Specialty RX, LLC.1 product
- Bionpharma Inc.1 product
- Dr. Reddy's Labratories Inc.1 product
- Remedyrepack Inc.1 product
FDA approval history
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
Generic approvals (8)
- ANDA205292Padagis Us · July 15, 2014
- ANDA202940Pharm Assoc · July 21, 2014
- ANDA203375Acella · September 20, 2016
- ANDA207676DR Reddys Labs SA · December 4, 2018
- ANDA213125Chartwell Molecular · April 17, 2020
- ANDA211170Adaptis · June 16, 2020
- ANDA210647Alkem Labs Ltd · July 14, 2020
- ANDA203997Bionpharma · September 30, 2020
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
March 15, 2021 · Class II · Terminated · D-0474-2021
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE, AND DEXTROMETHORPHAN HYDROBROMIDE SYRUP 10-30-2MG/5ML 473ML; NDC/UPC 71930-026-43; RX; SYRUP — Cardinal Health Inc.
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| RxCUI (RxNorm) | 1357010 |
|---|---|
| SPL set ID of the quoted label | f3afca82-ba8f-4741-8332-b7939aa0ee5e |
| FDA labels (SPL) | 18 |
| FDA applications | 8 ANDA |
| Active ingredients (FDA) | BROMPHENIRAMINE / DEXTROMETHORPHAN / PSEUDOEPHEDRINE |
Next steps
- Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
- Latest FDA drug recallsAll medicines, newest first
- Bryant Ranch PrepackMaker or distributor
- Acella Pharmaceuticals, LLCMaker or distributor
- Proficient Rx LPMaker or distributor
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Brompheniramine Maleate, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide, Sportpharm LLC, effective July 23, 2026; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →